Oncogenic addiction to high 26S proteasome level

Area of Science:

• Cellular Biology
• Cancer Research
• Biochemistry

Background:

• Cancer cells exhibit altered protein homeostasis, increasing their reliance on proteasome function.
• The 26S proteasome, composed of the 20S catalytic core and 19S regulatory particle, is crucial for protein degradation.
• Current proteasome inhibitors target the 20S core, hindering the study of distinct 20S vs. 26S proteasome roles.

Purpose of the Study:

• To investigate cancer cell dependency specifically on the 26S proteasome complex.
• To determine if targeting the 26S proteasome level can be a viable cancer therapy strategy.

Main Methods:

• Oncogenic transformation of cells with mutant Ras to induce 26S proteasome subunit increase.
• Depletion of 19S regulatory particle subunits to alter the 26S/20S ratio.
• Assessing cancer cell viability upon 26S proteasome reduction.
• Evaluating apoptosis markers (UPR, caspase-3, Annexin V) and morphological changes.

Main Results:

• Mutant Ras transformation increased 26S proteasome levels in human and mouse cells.
• Depleting a single 19S subunit reduced 26S proteasome levels, compromising Ras-transformed cell viability.
• Partial reduction of 26S proteasomes impaired viability in all tested cancer cell lines but not normal fibroblasts.
• Suppression of 26S proteasomes induced apoptosis, characterized by UPR activation, caspase-3, Annexin V positivity, and cellular deformation.

Conclusions:

• Cancer cell survival is critically dependent on maximal 26S proteasome utilization.
• Normal fibroblasts are resistant to 26S proteasome reduction, highlighting tumor cell-specific dependency.
• The 26S proteasome level represents a promising therapeutic target for cancer treatment.